logo
‘Perfectly preserved' Ice Age skull extracted from mine in the Canadian Klondike

‘Perfectly preserved' Ice Age skull extracted from mine in the Canadian Klondike

Miami Herald18-07-2025
At a placer mine in Canada's Klondike region, paleontologists made an unexpected and 'incredible' find.
Initially, only half an of an animal skull, including the jaw, was visibly sticking out of the ground at the Hester Creek mine, according to a June 27 Facebook post from the Yukon Beringia Interpretive Centre.
The team from Yukon Paleontology returned the next day with tools to safely thaw out the find, still solidly frozen in the earth.
Eager to help, the miners aimed their water hoses at the ground directly above the skull, 'which significantly sped up the excavation process,' experts said.
With the miners' assistance, the team removed a complete and 'perfectly preserved' Ice Age horse skull, according to the post.
'The presence of canines tells us this horse was likely male, and because they were only partially erupted, we know he was likely a teenager when he died,' officials said.
The depth at which the skull was found suggests the horse lived about 30,000 years ago, experts said in a Facebook comment.
'Many of the fossils coming out of this area are from the last Ice Age,' experts said.
Paleontologists have identified more than 50 different species of horses that roamed across North America, Europe and Eurasia during the Ice Age.
In the Yukon, the most common was Equus lambei, or the Yukon horse — a relatively small species that stood just under 4 feet tall at the shoulders, according to experts.
Another unique species found in the region toward the end of the Ice Age was the North American stilt-legged horse — characterized by long, thin leg bones and an overall lighter build, experts said.
Experts have not yet identified the species of the Hester Creek fossil. The mine is in Canada's Yukon territory.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

London team helps Jersey with archaeological finds
London team helps Jersey with archaeological finds

Yahoo

time2 days ago

  • Yahoo

London team helps Jersey with archaeological finds

Archaeologists from London are visiting Jersey to help catalogue and store hundreds of ice age animal bone from an ancient site. Jersey Heritage said while the items, found before 1960 at La Cotte de St Brelade, had been subjected to detailed work, the early finds were yet to be studied using modern scientific techniques. It said visitors could meet the team from the University College London (UCL) Institute of Archaeology for a free "Meet the Collections" event on Saturday at Sir Francis Cook Gallery. The finds, which are part of a Société Jersiaise collection, include a fragment of woolly mammoth bone and lots of pieces of horse, red deer, bison, and bear bones, said Jersey Heritage. It added the UCL team was interested in the remains of animals that may have been hunted by some of the last surviving Neanderthal groups in the region. Jersey Heritage said: "There is no reason why some of these fragments of bone might not be from the Neanderthal people themselves." More news stories for Jersey Listen to the latest news for Jersey Curator of archaeology at Jersey Heritage, Olga Finch, said: "It's great to have the expertise of the London team to undertake this curatorial work and provide a detailed catalogue, which the public and researchers can access to learn more about this important story in the Island's history." Dr Matt Pope from UCL said it was exciting to be involved in the "important process". "This is one of the most important collections of Ice Age animal bone in the region and we are getting every ready to unlock its secrets," he added. Follow BBC Jersey on X and Facebook. Send your story ideas to Related internet links Jersey Heritage UCL Institute of Archaeology More on this story New exhibition to explain history of Jersey Heritage releases historical Jersey records Gold award for Jersey Museum exhibit about island

These Popular Mushroom Kits Might Be Causing Environmental Harm
These Popular Mushroom Kits Might Be Causing Environmental Harm

Newsweek

time2 days ago

  • Newsweek

These Popular Mushroom Kits Might Be Causing Environmental Harm

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Bright yellow golden oyster mushrooms, prized for their nutty flavor and easy cultivation, have surged in popularity thanks to at-home growing kits. But new research warns that these kits may be unleashing an invasive species into North American forests. A study conducted by researchers in Wisconsin found that trees colonized by golden oyster mushrooms hosted about half as many native fungal species as those without them. DNA analysis from elm tree samples showed that the presence of this invasive fungus, Pleurotus citrinopileatus, reduced both the diversity and composition of native fungi. Stock image of mushrooms. Stock image of mushrooms. Photo by chengyuzheng / Getty Images Aishwarya Veerabahu, a co-author of the study and Ph.D. candidate at the University of Wisconsin-Madison, wrote in The Conversation that the invasive species had displaced fungi such as the mossy maze polypore and the elm oyster. According to Veerabahu, when native species are pushed out, researchers lose the opportunity to study their potential benefits. "I think [mushroom growers] very likely could introduce other types of invasive mushrooms," Veerabahu told Newsweek in an email. "I have my eye on the other non-native species of oyster mushrooms, but in truth it can be any." 'A simple but vital joy' Fungi serve as natural recyclers, breaking down dead wood and plant material and converting it into nutrients that enrich the soil. They also support climate regulation by storing carbon and helping other plants absorb water and nutrients. Disruption to these fungal communities could weaken forest ecosystems already strained by habitat loss and climate change. Veerabahu added that "the invasion of golden oysters risks erasing a simple, but vital, joy of seeing different, colorful, incredible fungi in the forest". "Every winter after the snow melts, fungi growing on dead wood are often the first ones to pop up, and I so love to see them again," she told Newsweek. "Golden oysters might make that experience non-existent. "Fungal biodiversity deserves to exist, period. Moving non-native fungi around the world puts fungal biodiversity at risk, along with everything they have to offer us: vital ecosystem processes, therapeutic medicines, and a deeper understanding of the natural world." What To Know The golden oyster mushroom, native to eastern Asia, was introduced to North America in the early 2000s and gained popularity through home-growing kits and cultivation on outdoor logs. While most cultivated mushrooms remain harmless, golden oysters have spread rapidly since escaping cultivation and are now reported in 25 U.S. states and parts of Canada. "As far as we know, this is the first cultivated species that has escaped," Veerabahu told Newsweek. "So even if a few people had an inkling, most people didn't know this could happen, and it's certainly not anyone's fault." What People Are Saying Veerabahu urged caution in The Conversation: "I recommend that people consider refraining from using golden oyster mushroom grow kits to prevent any new introductions. "For people who make a living selling these mushrooms, consider adding a note that this species is invasive and should be cultivated indoors and not composted." What's Next Veerabahu told Newsweek she plans to continue studying golden oyster mushrooms. Specifically, Veerabahu plans to examine whether the mushrooms have evolved to be genetically distinct from native populations. She also plans to examine the perspectives and priorities of stakeholders in golden oyster mushrooms and how they can be managed going forward.

Sobi Announces U.S. Food and Drug Administration Approves Doptelet® (avatrombopag) for the Treatment of Thrombocytopenia in Pediatric Patients One Year and Older with Persistent or Chronic Immune Thrombocytopenia (ITP)
Sobi Announces U.S. Food and Drug Administration Approves Doptelet® (avatrombopag) for the Treatment of Thrombocytopenia in Pediatric Patients One Year and Older with Persistent or Chronic Immune Thrombocytopenia (ITP)

Business Upturn

time3 days ago

  • Business Upturn

Sobi Announces U.S. Food and Drug Administration Approves Doptelet® (avatrombopag) for the Treatment of Thrombocytopenia in Pediatric Patients One Year and Older with Persistent or Chronic Immune Thrombocytopenia (ITP)

Doptelet Sprinkle (avatrombopag) was approved as an effective formulation for children one year to less than six years. The primary endpoint was met in 27.8% of patients, confirming the efficacy in children and adolescents with persistent or chronic ITP WALTHAM, Mass., July 25, 2025 (GLOBE NEWSWIRE) — Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi®), today announced that the U.S. Food and Drug Administration (FDA) approved Doptelet® (avatrombopag) for the treatment of thrombocytopenia in pediatric patients one year and older with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to a prior therapy. 1 The approval also includes a new formulation, Doptelet Sprinkle (avatrombopag) oral granules, for use in children ages one to less than six years. 1 'Doptelet represents a significant advancement in the treatment of children and adolescents with persistent or chronic ITP,' said Rachael Grace, MD, MMSc, Pediatric Hematologist and Director, Hematology Clinical Research at Dana-Farber/Boston Children's Cancer and Blood Disorders Center, and lead investigator of the AVA-PED-301 study. 'This therapy offers simple, flexible administration because it is oral, available as a tablet and now as a new pediatric sprinkle formulation and has no food restrictions. The approval of Doptelet for pediatric ITP offers families a new treatment option that can help address challenges in managing ITP in pediatric patients.' Doptelet Sprinkle is the approved dosage form for patients aged one to less than six years, while Doptelet tablet is the approved dosage form for patients aged six and up. 1 The pediatric approval is based on results from AVA-PED-301, a global, randomized, phase 3 study evaluating the efficacy, safety, and pharmacokinetics of Doptelet in the treatment of pediatric subjects with ITP. The study showed that 27.8% of Doptelet patients achieved the primary endpoint of durable platelet response* versus 0% of placebo patients in the absence of rescue medication (p=0.0077, 95% CI 15.8-39.7). Also, 81.5% of Doptelet patients achieved the alternative primary endpoint of platelet response** versus no patients in the placebo group (p=<0.0001, 95% CI 71.1-91.8). At Day 8, 55.6% of Doptelet patients (95% CI: 41.4%, 69.1%) had a platelet count ≥50×10^9/L in the absence of rescue therapy (p<0.0001) versus no placebo patients (95% CI: 0.0%, 16.1%). Doptelet was generally well-tolerated. In pediatric patients with persistent or chronic immune thrombocytopenia, the most common adverse reactions (≥ 10%) were viral infection, nasopharyngitis, cough, pyrexia, and oropharyngeal pain.1 'Since its introduction in 2019, Doptelet has been a cornerstone therapy for chronic ITP in adults,' said Duane Barnes, President of Sobi North America. 'This approval not only reinforces our commitment to innovation but also allows us to expand the treatment experience for patients and their families by offering Doptelet in two formulations.' Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by low numbers of platelets, leading to bruising and an increased risk of bleeding. It is estimated up to 100 people per million live with ITP. In children, ITP occurs in five out of 100,000 children per year and up to 25% of newly diagnosed pediatric ITP patients develop chronic ITP. Currently, no cure is available, and patients usually relapse after various treatments. Indications Doptelet is a thrombopoietin receptor agonist indicated for the treatment of: Thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure. Thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment Thrombocytopenia in pediatric patients 1 year and older with persistent or chronic immune thrombocytopenia who have had an insufficient response to a previous treatment Important Safety Information Doptelet is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic and thromboembolic complications in patients with chronic liver disease or immune thrombocytopenia. In patients with chronic liver disease, thromboembolic events (portal vein thrombosis) occurred in 0.4% (1/274) of patients receiving Doptelet. In adult patients with chronic immune thrombocytopenia, thromboembolic events (arterial or venous) occurred in 7% (9/128) of patients receiving Doptelet. Doptelet should not be administered to patients with chronic liver disease or immune thrombocytopenia in an attempt to normalize platelet counts. The most common adverse reactions in clinical trials were viral infection, nasopharyngitis, cough, pyrexia, and oropharyngeal pain. To report SUSPECTED ADVERSE REACTIONS, contact Sobi, Inc. at 1-866-773-5274 or FDA at 1-800-FDA-1088 or Please see the full Prescribing Information for Doptelet. * A durable response consisted of patients achieving a platelet count >=50,000/uL for six of the last eight weeks in the 12-week core phase of the AVA-PED-301 study. ** Efficacy was also evaluated by platelet response, defined as the proportion of subjects achieving at least two consecutive platelet assessments ≥50×10^9/L in the core phase in the absence of rescue medication. About Immune thrombocytopenia (ITP) Immune thrombocytopenia (ITP) is a rare, acquired autoimmune condition characterized by a low platelet count and an increased risk of bleeding, and represents a multi-faceted disease burden for children and adolescents. Bleeding can range from minor symptoms, such as bruising, to more severe findings such as intracranial hemorrhage. ITP can also have a significant impact on quality of life including severe fatigue and restrictions on physical activity due to risk of bleeding. About Doptelet® (avatrombopag) Doptelet is an orally administered thrombopoietin receptor agonist (TPO-RA) that mimics the biologic effects of TPO in stimulating the development and maturation of megakaryocytes, resulting in increased platelet count. It is approved by the US Food & Drug Administration (FDA) for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure and by the European Medicines Agency (EMA) for the treatment of severe thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo an invasive procedure. In June 2019, Doptelet was approved by the FDA for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment and in 2021, Doptelet was approved by EMA for the treatment of primary chronic ITP in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins). About Sobi North America As the North American affiliate of international biopharmaceutical company Sobi, the Sobi North America team is committed to Sobi's vision of being a leader in providing innovative treatments that transform lives for individuals with rare diseases. Our product portfolio includes multiple approved treatments focused on immunology, hematology and specialty care. With U.S. headquarters in the Boston area, Canadian headquarters in the Toronto area, and field sales, medical and market access representatives spanning North America, our growing team has a proven track record of commercial excellence. More information is available at or at About Sobi® Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at and LinkedIn. Contacts For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media, click here. References 1. Doptelet Prescribing Information. Doptelet U.S. Product Information. Last updated: July 2025. Morrisville, NC: AkaRx, Inc. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store